MedTrace Logo

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

NCT06016634 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-13

No results posted yet for this study

Summary

A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis

Conditions

Interventions

DRUG

Alendronate Sodium

Administer oral alendronate 70 mg once a week x 24 weeks to all study participants

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Doris Duke Charitable Foundation

    collaborator OTHER

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Oyebimpe O Adesina, MD, MS · UC Davis School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-09
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06016634 on ClinicalTrials.gov